Entrada Therapeutics, Inc. (TRDA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Entrada Therapeutics, Inc. (TRDA) closed at USD 4.55 on 2026-10-14, a change of -38.1 % over the past year, with a market capitalization of USD 186.12M.

Entrada Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Entrada Therapeutics, Inc. key figures

Previous close

USD 4.55 (2026-10-14)

1-year change

-38.1 %

Market cap

USD 186.12M

Enterprise value

USD -2.11M

P/E ratio (trailing)

-1.29

P/E ratio (forward)

-1.59

EPS (trailing)

-3.70

EPS (forward)

-3.01

PEG ratio

n/a

Price to book

0.74

Revenue growth

-53.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.99

Employees

152

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Entrada Therapeutics, Inc. and compare it with other stocks.